Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Latest news in HER2-low breast cancer

Paolo Tarantino • 5 Jun 2022
ASCO 2022
Breast Cancer Antibodies Trastuzumab deruxtecan
Daisy DESTINY-Breast04 DESTINY-Breast06

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of HER2-low breast cancer, an emerging field in breast cancer therapy. Low expression of HER2 is defined as an IHC score of 1+ or 2+ with a negative in situ hybridization (ISH) test, and recently, the results of DESTINY-Breast04 (NCT03734029) highlight the potential of HER2-targeted therapies in this distinct population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Paolo Tarantino

2:24
Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
Paolo Tarantino • 5 Jun 2023
1:29
Takeaways on the management of early-stage TNBC
Paolo Tarantino • 5 Jun 2023
2:23
Prognosis and trends in chemotherapy use for patients with stage IA TNBC
Paolo Tarantino • 5 Jun 2023
4:08
SABCS 2022 highlights
Paolo Tarantino • 8 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals